Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
SGN-TGT is a nonfucosylated monoclonal antibody targeting the immune checkpoint inhibitor TIGIT that binds to its target on tumor-infiltrating lymphocytes, inhibiting the interaction of TIGIT with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of the anti-tumor immune response (NCI Drug Dictionary; Annals of Oncology. 2020 Sep 1;31:S729-30).
|DrugClasses||TIGIT Antibody 17|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Axitinib + PF-06801591 + SGN-TGT||Axitinib PF-06801591 SGN-TGT||0||1|
|Pembrolizumab + SGN-TGT||Pembrolizumab SGN-TGT||0||1|